Two day conference for Pharmacists and nusing specializing in hematology/oncology. • 12 contact hours offered-2 law • Network with industry professionals • Enjoy breakfast, lunch, dinner & cocktail reception • Low fee to attend- including meals: Both days: Member-$100, Non members-$130 One day: Member-$85, Non member-$100

Upon completion of this activity, you will be able to: * describe the typical patient with mantle cell lymphoma. * describe the standard immunophenotype of mantle cell lymphoma. * identify the aggressive variants of mantle cell lymphoma. * discuss the prognostic implication of mantle cell lymphoma, blastoid and pleomorphic variants. * identify the pathognomonic cytogenetic abnormality seen in mantle cell lymphoma.

Scripps Clinic’s Division of Hematology & Oncology invites you to attend the 9th Annual Oncology Update. During this comprehensive course, clinical experts will review key findings from practice changing studies and the latest clinical data as presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting. Experts in the fields of hematology, lung, colorectal, breast and genitourinary cancers will focus on key results with the potential to change practice. Physicians will ...

Educational Objectives: At the conclusion of the course, participants should be able to: * Improve the diagnosis and treatment of common family practice problems * Apply traditional modes of diagnosis and management more effectively * Apply information to commonly asked questions in office practice * Increase proficiency and maintain competence by updating cognitive understanding of family medicine * Feel better prepared to pass the American Board of Family Medici...

This course is a comprehensive review of hematology/oncology that focuses on the clinical application of new research developments over the preceding year in the vast fields of hematology and oncology. Didactic presentations will be case-based. Attendees will leave with up-to-date, practical information which will have immediate clinical application.

The 2011 Pan Pacific Lymphoma Conference took place August 15-19 in Koloa, Hawaii. This newsletter provides a comprehensive review of key experimental and clinical data presented at the conference, with highlights in scientific advancement, knowledge, and insight gained from this scientific symposium.

James O. Armitage, MD, Richard I. Fisher, MD, and Julie M. Vose, MD, provide an analysis of key data on Lymphomas presented at the American Society of Hematology 2011 Annual Meeting.* Topics covered include: • Lymphoma in Pregnancy • Diffuse Large B-Cell Lymphoma • Follicular Lymphoma • Mantle Cell Lymphoma • Peripheral T-Cell Lymphoma • Novel Agents *CCO is an independent medical education company that provides state-of-the-art medical information to healthcare pr...

John C. Byrd, MD, and Kanti Rai, MD, provide an analysis of key data on chronic lymphocytic leukemia presented at the American Society of Hematology 2011 annual meeting*. Topics covered include: • Strategies for Frontline Therapy in Older Patients • Approaches for Relapsed/Refractory Disease • Novel Agents *CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other ed...

Mayo Clinic’s 15th Annual Internal Medicine Update: Sedona 2011 is a four-day course offering primary care physicians, nurse practitioners, and physician assistants a practical update on a variety of subspecialty topics including allergy, cardiovascular diseases, dermatology, endocrinology, gastroenterology, hematology, infectious diseases, integrative medicine, neurology, psychiatry, pulmonary, renal disease, rheumatology, travel medicine, and others applicable to today’s practice and pat...

Upon completion of this educational activity,the participant will be able to: 1.) Recognize how to classify anemias. 2.) Review the use of the CBC in the initial evaluation of anemia and subsequent appropriate lab tests.

Elias Jabbour, MD, and Jerald Radich, MD, provide an analysis of key data on Chronic Myeloid Leukemia presented at the American Society of Hematology 2011 Annual Meeting.* Topics covered include: • Treatment of Newly Diagnosed Chronic-Phase CML • Overcoming Resistance to Multiple Tyrosine Kinase Inhibitors • Low Level BCR-ABL Mutations and Treatment Response • Discontinuation of Tyrosine Kinase Inhibitor Therapy: Update of the STIM Study *CCO is an independent medical ...

Kenneth Anderson, MD; Sagar Lonial, MD; and Amitabha Mazumder, MD, provide an analysis of key data on multiple myeloma presented at the American Society of Hematology 2011 annual meeting.* Topics covered include: • Preclinical studies and studies in smoldering myeloma: cereblon expression in immunomodulatory drug–treated disease and QuiRedex study in smoldering myeloma • Treatment of patients with newly diagnosed or previously untreated multiple myeloma: MM-015, VISTA, carfilzomib, ...

Learning Objectives After completing this activity, the participant should be better able to recognize the signs, symptoms, and early laboratory findings associated with chronic lymphocytic leukemia (CLL). Target Audience This activity is targeted to any primary care provider who provides care to patients with an unexplained evelated white count for diagnosis of chronic lymphocytic leukemia (CLL).

The goal of this activity is to clarify challenging treatment issues of HER2+ breast cancer including incorporation of predictive and prognostic biomarker tests and evidence-based data into practice when determining individualized strategies that improve patient survival and quality of life.

Hemophilia treatment center clinicians need to remain well-versed in the latest clinical studies and trials to provide their patients with optimal care. However, not all members of hemophilia treatment teams have the opportunity to attend medical congresses, where the most up-to-date information regarding the treatment and management of patients with hemophilia is presented and discussed. This activity, derived from scientific posters and abstracts presented at recently held congresses, enable...

The goal of this educational activity is to enable oncologists and other healthcare professionals to optimize testing and targeted therapies to provide personalized care of HER2+ breast cancer patients.

Statement of Need/Program Overview Clinicians who treat patients with hemophilia, whether congenital or acquired, have many questions and observations about current issues and the clinical challenges they face when developing treatment strategies for their patients. Common inquiries include the clinical features of hemophilia, the treatment regimens utilized (including on-demand and prophylaxis), adherence and other barriers to optimal management, and dosing and administration of both factor ...

Advances in B Cell Biology: RA, SLE, and Vasculitis is a series of CME-accredited webcasts in which expert faculty bridge the gap between the complexities of current immunologic data and how they can be incorporated into clinical practice. The series is designed for busy clinicians interested in keeping abreast of cutting-edge data and novel therapies in treatment of ARDs – information that can have significant positive impacts on patient outcomes. Learning Objectives: -Recognize the rol...

This activity provides an update of recent clinical trial findings in the areas of colorectal cancer, hepatocellular carcinoma, pancreatic neuroendocrine tumors, and pancreatic adenocarcinoma based on data reported at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO). In addition, expert perspectives on the clinical and research implications of the study findings are presented. Upon completion of this activity, participants should be better able to: * Evaluate dat...

In this first of a series of grand rounds presentations, widely recognized multiple myeloma (MM) expert Dr. G. David Roodman invites you to join him in discussions of a “real-world” newly diagnosed MM patient. The case focuses on clinical features, required diagnostic work-up, patient staging, and risk-stratification. It also addresses common comorbidities including treatment prioritization, goals, and patient response assessment according to International Myeloma Working Group (IMWG) univ...

Non-small cell lung cancer (NSCLC) can no longer be considered a homogeneous disease. Histologic and molecular features of NSCLC predict response to targeted agents, as well as certain chemotherapies; therefore, therapy must be individualized according to these criteria to maximize patient outcomes. Gender should also play a role in the individualization of care, as lung cancer biology, natural history, and treatment outcomes vary between men and women. The rapid evolution of the treatment par...

Program Overview: Medical professionals who treat patients with leukemia need to be aware of new data showing improved outcomes for older individuals with acute myelogenous leukemia (AML) who receive less intensive therapy; assess options for less intensive therapy and how it can be integrated into practice for older individuals; and discuss new treatment options on the horizon. Presentation and case discussion by a leader in leukemia treatment addressing. - Intensive therapy in older in...

Internal Medicine Update 2012 offers practical and timely clinical recommendations and guidelines for general internists and subspecialists, family practice physicians, physician assistants, nurse practitioners and allied healthcare professionals. Several interactive, collaborative Breakout sessions of your choice, on topics relevant to your clinical practice, are available. Courses required for Florida medical license renewals (Medical Errors and Domestic Violence) are included. Sessions a...

Dr. Kaufman leads a discussion with a panel of renowned experts reviewing the latest clinical trial results for multiple myeloma throughout the life cycle of the disease including their views regarding the implications for practice from the 2011 American Society of Clinical Oncology (ASCO) annual meeting, filmed live Sunday, June 5, 2011 in Chicago, Illinois.

Dr. Raffini, M.D., is assistant professor of pediatrics -University of Pennsylvania School of Medicine, Philadelphia, PA and attending physician in the division of hematology -Children's Hospital of Philadelphia, Philadelphia, PA. She has completed a two-year National Hemophilia Foundation sponsored fellowship in clinical hemostasis. Here, she discusses inter alia, normal hemostasis, hemophilia, and VonWillebrand Disease. The author has no relationships with commercial interests related to ...

NEW: Free Shipping + Free CME Credits Whether preparing for your initial Pediatrics Board Certification exam or your Maintenance of Certification (MoC) exam, learning begins with the must-know material in MedStudy's newest Core Curriculum, the foundation of MedStudy’s overall learning system. The material in these 5 easy-to carry books not only correlates closely with the ABP exam blueprints (what you must know to pass both the initial and MoC Board exams) but also incorporates the most up-...

NEW! Free Shipping + Free CME Whether preparing for your initial IM Board Certification exam or your Maintenance of Certification (MoC) exam, learning begins with the must-know material in MedStudy's Core Curriculum, the foundation of MedStudy’s overall learning system. The material in these 5 easy-to carry books not only correlates closely with the ABIM exam blueprints (what you must know to pass both the initial and MoC Board exams) but also incorporates the most up-to-date, evidence-ba...

LEARNING OBJECTIVES After participating in this activity, the participant will demonstrate the ability to: Explain the role of newer agents in the treatment of patients with lymphoid leukemia Explain the role of autologous transplantation in multiple myeloma in 2011 Formulate patient management strategies using a risk-adapted approach to the treatment of lymphoid leukemia Identify optimal treatment approaches for patients with high risk multiple myeloma Discuss the unique management ...

The introduction of tyrosine kinase inhibitors (TKI) has transformed clinical management of chronic myeloid leukemia (CML). Although most patients with CML who are receiving TKI therapy achieve clinically significant hematologic, cytogenetic, and molecular responses, the durability of these responses is limited by the development of mutation-induced drug resistance and drug-related toxicities. Evidence-based guidelines have been evolving since the introduction of imatinib. Recommendations for ...

HER2-positive breast cancer, which affects approximately one-fourth of patients with breast cancer, is an aggressive malignancy with proven resistance to standard treatments. However, progress is being made in the treatment of this type of breast cancer, with the advent of targeted therapies. Accurate determination of HER2 status is therefore imperative to identify patients who can benefit from these therapies. Numerous novel therapies are emerging, and strategies assessing the benefits of com...